Why we're lowering our Bristol Myers price target despite an earnings beat, guidance raise
Shares of Bristol Myers Squibb fell modestly after the drugmaker's better-than-expected first-quarter results.
Bristol Myers
since
auto-detected in 16 stories
10 days ago
50 days ago
JPMorgan says own this drug stock. It's one Jim Cramer is itching to buy again
The Club remains optimistic about Bristol Myers and shares JPMorgan's enthusiasm about Cobenfy.
page 1 of 1